search
Back to results

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

Primary Purpose

Opioid-Related Disorders

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine
Sponsored by
National Institute on Drug Abuse (NIDA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid-Related Disorders focused on measuring opiate dependence

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Currently opioid dependent In good health, as determined by a pre-participation medical examination Seeking and eligible for methadone maintenance or detoxification treatment Exclusion Criteria: Significant medical or psychiatric illness, other than drug dependence

Sites / Locations

  • Johns Hopkins University (BPRU) Bayview Campus

Outcomes

Primary Outcome Measures

Opioid agonist rating
opiate withdrawal
physiologic measures

Secondary Outcome Measures

Full Information

First Posted
August 23, 2005
Last Updated
January 11, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00134914
Brief Title
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
Official Title
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals
Study Type
Interventional

2. Study Status

Record Verification Date
July 2008
Overall Recruitment Status
Completed
Study Start Date
August 1996 (undefined)
Primary Completion Date
April 1998 (Actual)
Study Completion Date
May 1998 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to examine the effects of buprenorphine/naloxone when given through different routes and at different doses.
Detailed Description
Buprenorphine, a mixed agonist-antagonist opioid (or partial agonist), is a safe and effective treatment for opioid dependence. However, there is concern that buprenorphine may be abused due to its high abuse potential. A sublingual buprenorphine/naloxone combination tablet may reduce the risk of abuse associated with buprenorphine alone. The purpose of this study is to characterize the effects of buprenorphine/naloxone in opioid-dependent individuals. This study will last 10 weeks. Participants will stay in a residential research unit, and will be maintained on oral hydromorphone (10 mg). During twice-weekly experimental sessions, participants will be randomly assigned to receive either sublingual tablets, intramuscular injections, or a placebo. The 15 conditions studied will include: sublingual or intramuscular buprenorphine/naloxone (1/0.25 mg, 2/0.5 mg, 4/1 mg, 8/2 mg, and 16/4 mg), 0.25 mg of intramuscular naloxone (antagonist control), 10 mg of intramuscular hydromorphone (agonist control), sublingual and intramuscular buprenorphine (8 mg), and placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders
Keywords
opiate dependence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Buprenorphine
Intervention Description
single doses given by sublingual and parenteral routes
Primary Outcome Measure Information:
Title
Opioid agonist rating
Time Frame
up to one day
Title
opiate withdrawal
Time Frame
up to one day
Title
physiologic measures
Time Frame
up to one day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Currently opioid dependent In good health, as determined by a pre-participation medical examination Seeking and eligible for methadone maintenance or detoxification treatment Exclusion Criteria: Significant medical or psychiatric illness, other than drug dependence
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric C. Strain, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins University (BPRU) Bayview Campus
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224 6823
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11351930
Citation
Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001 Mar;154(3):230-42. doi: 10.1007/s002130000637.
Results Reference
result

Learn more about this trial

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

We'll reach out to this number within 24 hrs